NCT03347266 is a Phase 2 clinical trial of VVZ-149 injections in Post-Operative Pain, sponsored by Vivozon, Inc..

Who is sponsoring NCT03347266?

NCT03347266 is sponsored by Vivozon, Inc..

What drugs are being tested in NCT03347266?

Interventions in NCT03347266: VVZ-149 injections, Placebo.

What condition does NCT03347266 study?

NCT03347266 studies Post-Operative Pain.

Is NCT03347266 still recruiting?

NCT03347266 is currently completed. Last updated 13 March 2019.

Last reviewed 2019-03-13 · How we verify

NCT03347266

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluate the Analgesic Efficacy and Safety of VVZ-149 Injection for Postoperative Pain Following Total Hip Arthroplasty.

Completed Phase 2 Last updated 13 March 2019

What this trial tests

Phase 2 trial testing VVZ-149 injections in Post-Operative Pain in 12 participants. Completed in 19 July 2018.

Timeline

20 December 2017

Primary endpoint
19 July 2018

19 July 2018

Quick facts

Lead sponsor	Vivozon, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	triple
Primary purpose	treatment
Enrollment	12
Start date	20 December 2017
Primary completion	19 July 2018
Estimated completion	19 July 2018
Sites	1 location across South Korea

Drugs / interventions tested

VVZ-149 injections — full drug profile →
Placebo

Conditions studied

Post-Operative Pain — all drugs for Post-Operative Pain →

Sponsor

Vivozon, Inc. — full company profile →

Who can join

Adults 25 to 65, any sex, with Post-Operative Pain. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this phase 2 study is to evaluate the efficacy and safety of an analgesic drug candidate, VVZ-149 Injections. The study is designed as randomized, double-blind, parallel, and placebo-controlled study.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Inhibition of Glycine Re-Uptake: A Potential Approach for Treating Pain by Augmenting Glycine-Mediated Spinal Neurotransmission and Blunting Central Nociceptive Signaling.
Cioffi CL. · · 2021 · cited 18× · PMID 34200954 · DOI 10.3390/biom11060864

Verify or expand the search:

Other Vivozon, Inc. trials

Trials by the same sponsor.

NCT04415645 — Absorption, Metabolism, Excretion, and Mass Balance Study of [14C]-VVZ-149 in Healthy Adult Male Subjects · Phase 1 · completed
NCT03997838 — Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Post-Operative Pain Following Abdominoplasty · Phase 3 · completed
NCT03997812 — Evaluate the Efficacy and Safety of VVZ-149 Injections for the Treatment of Postoperative Pain Following Bunionectomy · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03347266 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Vivozon, Inc.
Last refreshed: 13 March 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03347266.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing